Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report 2026

The chronic inflammatory demyelinating polyneuropathy (cidp) market size has grown strongly in recent years. It will grow from $2.27 billion in 2025 to $2.46 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to improved awareness of rare autoimmune neuropathies, wider availability of ivig therapies, advancements in electrodiagnostic testing, increased specialist neurology care, better recognition of cidp subtypes.

The chronic inflammatory demyelinating polyneuropathy (cidp) market size is expected to see strong growth in the next few years. It will grow to $3.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing development of targeted immunotherapies, rising focus on minimizing treatment side effects, expansion of remote patient monitoring, growing demand for sustained remission therapies, increasing investments in rare disease research. Major trends in the forecast period include increasing use of ivig as first-line therapy, rising adoption of personalized treatment regimens, growing integration of advanced diagnostic tools, expansion of home-based treatment models, enhanced focus on long-term disease management.

Rising healthcare expenditure is anticipated to support the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market in the coming years. The increase in healthcare spending is driven by higher investments in medical infrastructure, growing demand for advanced therapies, expanded insurance coverage, and government initiatives aimed at improving healthcare access. Higher healthcare expenditure improves access to advanced treatments, enables earlier diagnosis, and supports more effective management of CIDP, leading to improved patient outcomes and quality of life. For example, in May 2024, data from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, representing a notable rise compared to the 0.9% growth recorded in 2022. As a result, increasing healthcare expenditure is contributing to the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.

Companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are increasingly focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, enhance patient outcomes, and enable more targeted and efficient immune modulation in CIDP management. Intravenous immunoglobulin (IVIG) therapy involves the infusion of concentrated antibodies obtained from healthy donors to regulate immune responses and reduce inflammation associated with autoimmune disorders. For instance, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval permits its use as an induction therapy, beginning with an initial dose followed by maintenance dosing to support long-term disease control and improved neuromuscular function.

In November 2024, Zai Lab Limited, a China-based biopharmaceutical company, entered into a partnership with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for chronic inflammatory demyelinating polyneuropathy (CIDP) in China. This collaboration is intended to deliver a convenient, effective, and well-tolerated treatment option that addresses unmet medical needs and enhances patient outcomes. argenx SE is a Netherlands-based biotechnology company focused on developing innovative therapies for severe autoimmune conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP).

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma.

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the CIDP market by increasing costs of imported immunoglobulins, biologic drugs, diagnostic equipment, and plasma-derived therapy components. North America and Europe are most affected due to dependence on imported plasma products and specialized diagnostics, while Asia-Pacific faces higher production and export costs. These tariffs are contributing to higher treatment expenses and reimbursement challenges. However, they are also supporting domestic plasma collection initiatives, local biologics manufacturing, and improved regional self-sufficiency in CIDP treatment supply chains.

The chronic inflammatory demyelinating polyneuropathy (cidp) market research report is one of a series of new reports that provides chronic inflammatory demyelinating polyneuropathy (cidp) market statistics, including chronic inflammatory demyelinating polyneuropathy (cidp) industry global market size, regional shares, competitors with a chronic inflammatory demyelinating polyneuropathy (cidp) market share, detailed chronic inflammatory demyelinating polyneuropathy (cidp) market segments, market trends and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (cidp) industry. This chronic inflammatory demyelinating polyneuropathy (cidp) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon autoimmune condition characterized by progressive muscle weakness and reduced sensory function caused by inflammation and demyelination of peripheral nerves. The disorder occurs when the immune system mistakenly attacks the myelin sheath surrounding peripheral nerves, resulting in muscle weakness, numbness, and difficulties with coordination.

The primary treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP) include intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and other therapies. Intravenous immunoglobulin (IVIg) is a plasma-derived blood product containing pooled antibodies that is used to treat autoimmune disorders, immune deficiencies, and inflammatory conditions by regulating immune responses. These therapies are delivered through multiple routes, such as intravenous, oral, and other methods, while diagnosis generally involves electrodiagnostic evaluations, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and additional diagnostic techniques. Treatment distribution channels include hospitals, pharmacies, online pharmacies, and specialty clinics, with key end users being hospitals, research institutions, and homecare environments.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.